share_log

Around $2M Bet On This Health Care Stock? Check Out These 3 Stocks Under $5 Insiders Are Aggressively Buying

Around $2M Bet On This Health Care Stock? Check Out These 3 Stocks Under $5 Insiders Are Aggressively Buying

約$200萬人民幣押注醫療保健股票？看看以下這3只股票，內部人員正在積極購買
Benzinga ·  08/19 19:48

The Dow Jones index closed higher by around 100 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

道瓊斯指數週五收盤上漲約100點。當內部人買入或賣出股票時，表明他們對公司前景的信心或擔憂。對於有興趣購買低價股票的投資者和交易者，他們可以考慮這一因素作爲他們整體投資或交易決策的因素。

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

以下是幾個近期關於低價股的值得關注的內部交易。了解更多，請查看Benzinga內幕交易平台。

Pineapple Financial

菠蘿融資

  • The Trade: Pineapple Financial Inc. (NYSE:PAPL) CEO Shubha-Jeet Dasgupta bought a total of 2,000 shares at an average price of $1.08. To acquire these shares, it cost around $2,160.
  • What's Happening: On July 16, Pineapple Financial posted a wider-than-expected quarterly loss.
  • What Pineapple Financial Does: Pineapple Financial Inc is a Canada-based mortgage technology and brokerage company that provides mortgage brokerage services and technology solutions to Canadian mortgage agents, brokers, sub-brokers, brokerages, and consumers.
  • 交易：菠蘿金融公司（紐交所：PAPL）首席執行官Shubha-Jeet Dasgupta以平均價格1.08美元購買了總計2000股。購買這些股票的成本約爲2160美元。
  • 最新消息：7月16日，Pineapple Financial公佈了一季度的虧損超出預期。
  • Pineapple Financial Inc是一家加拿大抵押貸款科技和券商公司，爲加拿大抵押貸款經紀人、券商、子券商、券商和消費者提供抵押貸款經紀服務和技術解決方案。

ProMIS Neurosciences

ProMIS神經科學

  • The Trade: ProMIS Neurosciences, Inc. (NASDAQ:PMN) Director Patrick D. Kirwin acquired a total of 10,000 shares at an average price of $1.25. To acquire these shares, it cost around $12,492.
  • What's Happening: On Aug. 8, ProMIS Neurosciences posted a second-quarter GAAP loss of 13 cents per share.
  • What ProMIS Neurosciences Does: ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA).
  • 交易：ProMIS神經科學公司（納斯達克：PMN）董事Patrick D. Kirwin以平均價格1.25美元購買了總計1萬股。購買這些股票的成本約爲12492美元。
  • 正在發生的事情：8月8日，ProMIS神經科學發佈了第二季度GAAP虧損每股13美分的業績。
  • ProMIS神經科學做什麼：ProMIS神經科學公司是一家臨床階段的生物技術公司，專注於生成和開發選擇性靶向神經退行性疾病（如阿爾茨海默病（AD）、肌萎縮性側索硬化（ALS）和多系統萎縮（MSA））中有毒錯位蛋白的抗體治療藥物。

Standard BioTools

標準生物工具

  • The Trade: Standard BioTools Inc. (NASDAQ:LAB) Director Eli Casdin acquired a total of 1,200,000 shares at an average price of $1.59. The insider spent around $1.9 million to buy those shares.
  • What's Happening: On July 31, Standard BioTools reported worse-than-expected quarterly financial results and cut FY24 revenue guidance below estimates.
  • What Standard BioTools Does: Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively.
  • 交易：Standard BioTools公司（納斯達克：LAB）董事Eli Casdin以平均價格1.59美元買入了總計120萬股。這位內部人花費約190萬美元購買這些股票。
  • 正在發生的事情：7月31日，Standard BioTools報告了比預期更糟糕的季度財務結果，並將FY24營收指南下調至預期以下。
  • Standard BioTools公司做什麼：Standard BioTools公司開發、製造和銷售能夠幫助生物醫學研究人員更快地開發藥物的技術。其工具使用專有的質量細胞術和微流控技術爲蛋白質組學和基因組學等領域的應用提供了洞察力。
  • Jim Cramer Recommends Buying Clorox: 'CEO Has Done Remarkable Job'
  • 吉姆·克萊默推薦購買高樂氏：'CEO表現出色'

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論